U.S. markets open in 1 hour 32 minutes

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
7.43+0.06 (+0.81%)
At close: 4:00PM EST

7.65 +0.22 (2.96%)
Before hours: 7:48AM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
Previous Close7.37
Open7.50
Bid0.00 x 1400
Ask7.96 x 800
Day's Range7.36 - 7.70
52 Week Range3.26 - 11.35
Volume424,379
Avg. Volume317,898
Market Cap308.991M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why RedHill Biopharma Stock Is Tanking Today
    Motley Fool

    Why RedHill Biopharma Stock Is Tanking Today

    The decline came after the specialty biopharmaceutical company announced that it was increasing the size of its previously announced public stock offering. RedHill now plans to offer nearly 3.2 million American depositary shares (ADSs) at a price of $7.84 per share. There's good news and bad news with RedHill's decision to increase the size of its public stock offering.

  • RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation
    Zacks

    RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

    RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

  • RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study
    Zacks

    RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study

    RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.